Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer

被引:253
作者
Yoshida, Takeichi [1 ]
Kato, Jun [1 ]
Inoue, Izumi [1 ]
Yoshimura, Noriko [2 ]
Deguchi, Hisanobu [1 ]
Mukoubayashi, Chizu [1 ]
Oka, Masashi [1 ]
Watanabe, Mika [1 ]
Enomoto, Shotaro [1 ]
Niwa, Toru [1 ]
Maekita, Takao [1 ]
Iguchi, Mikitaka [1 ]
Tamai, Hideyuki [1 ]
Utsunomiya, Hirotoshi [1 ]
Yamamichi, Nobutake [3 ]
Fujishiro, Mitsuhiro [3 ]
Iwane, Masataka [4 ]
Takeshita, Tatsuya [5 ]
Ushijima, Toshikazu [6 ]
Ichinose, Masao [1 ]
机构
[1] Wakayama Med Univ, Sch Med, Dept Internal Med 2, Wakayama 6410012, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Joint Dis Res, Bunkyo Ku, Tokyo, Japan
[3] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo, Japan
[4] Wakayama Wellness Fdn, Wakayama, Japan
[5] Wakayama Med Univ, Sch Med, Dept Publ Hlth, Wakayama 6410012, Japan
[6] Natl Canc Ctr, Res Inst, Div Epigen, Chuo Ku, Tokyo 104, Japan
关键词
atrophic gastritis; Helicobacter pylori; cohort study; pepsinogen; cancer high-risk; gastric cancer; SELECTIVE CYCLOOXYGENASE-2 INHIBITOR; E-CADHERIN GENE; HIGH-RISK; MONGOLIAN GERBILS; STOMACH CARCINOGENESIS; INFECTION; LESIONS; JAPAN; POPULATION; COHORT;
D O I
10.1002/ijc.28470
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Our study investigated the relationship between gastric cancer development and activity of Helicobacter pylori-associated chronic gastritis or the resulting chronic atrophic gastritis (CAG). A cohort of 4,655 healthy asymptomatic subjects, in whom serum pepsinogen (PG) and H. pylori antibody titer had been measured to assess the activity and stage of H. pylori-associated chronic gastritis, was followed for up to 16 years, and cancer development was investigated. In subjects with a serologically diagnosed healthy stomach (H. pylori-negative/CAG-negative), cancer incidence rate was low, at 16/100,000 person-years. With the establishment of H. pylori infection and progression of chronic gastritis, significant stepwise cancer risk elevations were seen from CAG-free subjects (H. pylori-positive/CAG-negative) [hazard ratio (HR)=8.9, 95% confidence interval (CI)=2.7-54.7] to subjects with CAG (H. pylori-positive/CAG-positive) (HR=17.7, 95% CI=5.4-108.6) and finally to subjects with metaplastic gastritis (H. pylori-negative/CAG-positive) (HR=69.7, 95% CI=13.6-502.9). In H. pylori-infected CAG-free subjects, significantly elevated cancer risk was observed in the subgroup with active inflammation-based high PG II level or potent immune response-based high H. pylori antibody titer; the former was associated with a particularly high risk of diffuse-type cancer, and both subgroups showed high cancer incidence rates of around 250/100,000 person-years, comparable to that in subjects with CAG. No such risk elevation was observed in H. pylori-infected subjects with CAG. These results clearly indicate that gastric cancer develops mainly from the gastritis-atrophy-metaplasia-cancer sequence and partly from active inflammation-based direct carcinogenesis, and that serum levels of PG and H. pylori antibody titer provide indices of cancer development in H. pylori-infected subjects. What's new? Infection with the bacteria H. pylori is the most common risk factor for developing gastric cancer. The infection causes chronic inflammation leading to a sequence of gastritis, atrophy, metaplasia, dysplasia, cancer. This study follows up a cohort of 6,000 men after 16 years and showed that cancer risk increased with the progression of inflammation and atrophy, which can be measured by serum tests. These tests, the authors suggest, would be useful in assessing risk among people infected with H. pylori.
引用
收藏
页码:1445 / 1457
页数:13
相关论文
共 50 条
[1]
[Anonymous], 2001, CANC SCREENING COMMO
[2]
Review article:: gastric cancer and Helicobacter pylori [J].
Axon, A .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 :83-88
[3]
Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer [J].
Chan, AOO ;
Lam, SK ;
Wong, BCY ;
Wong, WM ;
Yuen, MF ;
Yeung, YH ;
Hui, WM ;
Rashid, A ;
Kwong, YL .
GUT, 2003, 52 (04) :502-506
[4]
Serodiagnosis of Helicobacter pylori infection: Comparison and correlation between enzyme-linked immunosorbent assay and rapid serological test results [J].
Chen, TS ;
Chang, FY ;
Lee, SD .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) :184-186
[5]
Does Helicobacter pylori cause gastric cancer via oxidative stress? [J].
Correa, P .
BIOLOGICAL CHEMISTRY, 2006, 387 (04) :361-364
[6]
CORREA P, 1992, CANCER RES, V52, P6735
[7]
Carcinogenesis of Helicobacter pylori [J].
Correa, Pelayo ;
Houghton, Jeanmarie .
GASTROENTEROLOGY, 2007, 133 (02) :659-672
[8]
Stomach - Genetic and epigenetic alterations of preneoplastic and neoplastic lesions [J].
David, Stefan ;
Meltzer, Stephen J. .
CANCER BIOMARKERS, 2011, 9 (1-6) :493-507
[9]
Gastric cancer risk in patients with premalignant gastric lesions: A nationwide cohort study in the Netherlands [J].
de Vries, Annemarie C. ;
van Grieken, Nicole C. T. ;
Looman, Caspar W. N. ;
Casparie, Mariel K. ;
de Vries, Esther ;
Meijer, Gerrit A. ;
Kuipers, Ernst J. .
GASTROENTEROLOGY, 2008, 134 (04) :945-952
[10]
CHRONIC ACTIVE GASTRITIS DUE TO HELICOBACTER-PYLORI IN IMMUNIZED GNOTOBIOTIC PIGLETS [J].
EATON, KA ;
KRAKOWKA, S .
GASTROENTEROLOGY, 1992, 103 (05) :1580-1586